Login to Your Account

AstraZeneca: Joint Approach in Amylin Deal 'Made Sense'

By Nuala Moran
Staff Writer

Thursday, July 5, 2012
After Bristol-Myers Squibb Co. announced the acquisition of Amylin Pharmaceuticals Inc. late Friday afternoon, it emerged that the deal is to be a 50-50 joint purchase with AstraZeneca plc, and that all Amylin's assets are to be placed in the Type II diabetes collaboration the two pharma companies established in January 2007.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription